ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
This Quarter Return
+5.12%
1 Year Return
+4.95%
3 Year Return
+16.8%
5 Year Return
+58.39%
10 Year Return
–
AUM
$77.6M
AUM Growth
+$77.6M
(-60%)
Cap. Flow
-$119M
Cap. Flow
% of AUM
-153.06%
Top 10 Holdings %
Top 10 Hldgs %
64.82%
Holding
61
New
11
Increased
2
Reduced
17
Closed
30
Top Buys
| 1 |
Agilent Technologies
A
|
$5.5M |
| 2 |
IQVIA
IQV
|
$4.31M |
| 3 |
Boston Scientific
BSX
|
$3.3M |
| 4 |
Cardinal Health
CAH
|
$3M |
| 5 |
Medtronic
MDT
|
$2.39M |
Top Sells
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$18.4M |
| 2 |
Becton Dickinson
BDX
|
$16.8M |
| 3 |
Elevance Health
ELV
|
$14.1M |
| 4 |
Sabra Healthcare REIT
SBRA
|
$13.4M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$6.75M |
Sector Composition
| 1 | Healthcare | 97.47% |
| 2 | Real Estate | 2.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Healthpeak Properties
DOC
$12.3B
| – | – |
-100,685
| Closed | -$2.21M |
|
52
Cencora
COR
$57.2B
| – | – |
-9,153
| Closed | -$1.47M |
|
53
Centene
CNC
$14.8B
| – | – |
-29,586
| Closed | -$1.87M |
|
54
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| – | – |
-64,956
| Closed | -$444K |
|
55
BioXcel Therapeutics
BTAI
$52.7M
| – | – |
-11,640
| Closed | -$217K |
|
56
Bio-Rad Laboratories Class A
BIO
$7.8B
| – | – |
-9,185
| Closed | -$4.4M |
|
57
Biodesix
BDSX
$61.9M
| – | – |
-113,267
| Closed | -$211K |
|
58
Baxter International
BAX
$12.1B
| – | – |
-34,508
| Closed | -$1.4M |
|
59
Avantor
AVTR
$8.74B
| – | – |
-225,615
| Closed | -$4.77M |
|
|
ADXN
60
Addex Therapeutics
ADXN
$8.65M
| – | – |
-120,748
| Closed | -$114K |
|
61
Aclaris Therapeutics
ACRS
$223M
| – | – |
-83,891
| Closed | -$679K |
|